Ex-Dividend Alert: Gilead Sciences, Merck, and Horace Mann Educators
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 11 2025
0mins
Should l Buy GILD?
Source: NASDAQ.COM
Upcoming Ex-Dividend Dates: Gilead Sciences Inc (GILD), Merck & Co Inc (MRK), and Horace Mann Educators Corp. (HMN) will trade ex-dividend on 12/15/25, with respective dividends of $0.79, $0.85, and $0.35 scheduled for payment on 12/30/25, 1/8/26, and 12/31/25.
Expected Stock Price Adjustments: Following the ex-dividend date, GILD shares are expected to open 0.65% lower, MRK by 0.87%, and HMN by 0.78%, based on their recent stock prices.
Dividend Yield Estimates: The estimated annualized yields for the upcoming dividends are 2.60% for Gilead, 3.48% for Merck, and 3.11% for Horace Mann, reflecting their historical dividend stability.
Current Trading Performance: As of Thursday trading, shares of Gilead Sciences, Merck, and Horace Mann are up approximately 1.7%, 0.8%, and 1.4%, respectively.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GILD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GILD
Wall Street analysts forecast GILD stock price to fall
19 Analyst Rating
16 Buy
3 Hold
0 Sell
Strong Buy
Current: 147.120
Low
105.00
Averages
137.88
High
154.00
Current: 147.120
Low
105.00
Averages
137.88
High
154.00
About GILD
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. It is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. It also develops the HB-400 program and the HB-500 program. It develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. It has a cancer program, namely TREX1. It operates in more than 35 countries worldwide.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Novartis and Genentech Sue Over Drug Importation
- Drug Import Lawsuit: Novartis and Genentech have filed a lawsuit against a U.S. company and a Canadian pharmacy for the illegal importation of the allergy medication Xolair, which poses potential risks to patient safety, seeking a court order to halt this practice.
- FDA Regulatory Violations: The lawsuit claims that this importation violates U.S. Food and Drug Administration regulations, as biological medicines like Xolair are highly sensitive to storage and handling conditions, which could lead to contamination and reduced efficacy.
- Rise of Alternative Funding Programs: A CNBC investigation reveals a growing number of alternative funding programs in the U.S., despite federal officials warning that such imports are illegal and could jeopardize patient health.
- Patient Safety Risks: The lawsuit underscores that importing unapproved medications can result in serious patient injuries or even death, with Novartis and Genentech aiming to protect patients from these potential health threats.
See More
Novartis and Genentech Sue Over Illegal Drug Import Scheme
- Illegal Drug Importation: Novartis and Genentech have filed a lawsuit against SHARx and a Canadian pharmacy for allegedly violating FDA regulations by illegally importing the allergy medication Xolair from Canada to the U.S., posing potential health risks to patients.
- Legal Action Context: The lawsuit, filed on February 2 in the U.S. District Court in Michigan, seeks to halt the importation of the drug, emphasizing the sensitivity of biological medicines to storage and handling conditions, which could lead to contamination and degradation.
- Patient Safety Risks: The complaint highlights that importing unapproved drugs can result in serious patient injuries or even death, stressing the strict temperature control requirements during drug transport, thereby underscoring the dangers of such practices.
- Market Regulation Challenges: This case reflects the growing legal gray area surrounding alternative funding programs (AFPs) in drug access, with federal authorities warning about the illegality of such imports, which could threaten patient health.
See More
Analysis of DFAC Stock's 52-Week High and Low Points
- Price Fluctuation Analysis: DFAC's 52-week low is $28.39 and high is $41.64, with the latest trade at $41.00, indicating the stock is nearing its high point, which may attract investor interest.
- Technical Analysis Tool: Comparing the latest stock price to the 200-day moving average can provide valuable insights for investors, helping to assess market trends.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting ETF liquidity.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding for ETFs helps identify those experiencing significant inflows or outflows, allowing assessment of their potential impact on underlying assets.
See More
Barron’s Top Fund Families for 2025
Opportunity for Fund Managers: Last year provided a significant opportunity for skilled fund managers to demonstrate their capabilities in navigating market challenges.
Market Conditions: The financial landscape presented unique conditions that allowed for strategic investment decisions and potential gains.
Performance Evaluation: The year served as a benchmark for assessing the effectiveness and decision-making skills of fund managers.
Investor Expectations: Investors were keenly observing how fund managers adapted to the evolving market, influencing future investment strategies.
See More
Gilead's BIC/LEN Pill Maintains Viral Suppression in HIV Trials
- Clinical Trial Results: In the ARTISTRY-1 trial, only 0.8% of patients on BIC/LEN had HIV-1 RNA ≥ 50 copies/mL, demonstrating comparable viral suppression to multi-tablet regimens, indicating the drug's effectiveness in maintaining viral control.
- Comparative Analysis: In ARTISTRY-2, 1.3% of BIC/LEN participants had HIV-1 RNA ≥ 50 copies/mL compared to 1.0% of those continuing on Biktarvy, suggesting BIC/LEN's efficacy is similar to existing treatment options, potentially influencing patient medication choices.
- Switching Advantages: BIC/LEN allows patients to switch from complex multi-drug regimens while maintaining viral suppression, simplifying treatment and potentially improving patient adherence and quality of life.
- Market Outlook: Gilead's new drug shows similar efficacy to Biktarvy, which may help it carve out a niche in the HIV treatment market, enhancing the company's competitive position in the antiviral drug sector.
See More
Gilead's New Drug Combination Shows Significant Efficacy in HIV Treatment
- Clinical Trial Results: Gilead's presentation at CROI 2026 of ARTISTRY-1 and ARTISTRY-2 trial results indicates that the BIC/LEN combination is non-inferior to complex multi-tablet regimens in maintaining HIV viral suppression, with 0.8% of participants on BIC/LEN having HIV-1 RNA ≥ 50 copies/mL at 48 weeks compared to 1.1% in the complex regimen, highlighting its therapeutic potential.
- Increased Patient Satisfaction: At 48 weeks, patient-reported treatment satisfaction in the BIC/LEN group increased by an average of 7 points, while those on complex regimens reported no significant change, indicating the new combination's advantages in patient experience and adherence.
- Good Safety Profile: The BIC/LEN combination was generally well tolerated, with drug-related adverse events reported in 14.3% of participants switching to BIC/LEN compared to 1.6% in the complex regimen, and similar rates of serious adverse events, demonstrating the safety of the new treatment option.
- Strategic Implications: These findings support Gilead's commitment to innovation in HIV treatment, as the BIC/LEN combination is poised to become a new treatment option, further expanding HIV treatment alternatives and addressing patient needs for more convenient therapies.
See More
Novartis and Genentech Sue Over Drug Importation
- Drug Import Lawsuit: Novartis and Genentech have filed a lawsuit against a U.S. company and a Canadian pharmacy for the illegal importation of the allergy medication Xolair, which poses potential risks to patient safety, seeking a court order to halt this practice.
- FDA Regulatory Violations: The lawsuit claims that this importation violates U.S. Food and Drug Administration regulations, as biological medicines like Xolair are highly sensitive to storage and handling conditions, which could lead to contamination and reduced efficacy.
- Rise of Alternative Funding Programs: A CNBC investigation reveals a growing number of alternative funding programs in the U.S., despite federal officials warning that such imports are illegal and could jeopardize patient health.
- Patient Safety Risks: The lawsuit underscores that importing unapproved medications can result in serious patient injuries or even death, with Novartis and Genentech aiming to protect patients from these potential health threats.
See More
Novartis and Genentech Sue Over Illegal Drug Import Scheme
- Illegal Drug Importation: Novartis and Genentech have filed a lawsuit against SHARx and a Canadian pharmacy for allegedly violating FDA regulations by illegally importing the allergy medication Xolair from Canada to the U.S., posing potential health risks to patients.
- Legal Action Context: The lawsuit, filed on February 2 in the U.S. District Court in Michigan, seeks to halt the importation of the drug, emphasizing the sensitivity of biological medicines to storage and handling conditions, which could lead to contamination and degradation.
- Patient Safety Risks: The complaint highlights that importing unapproved drugs can result in serious patient injuries or even death, stressing the strict temperature control requirements during drug transport, thereby underscoring the dangers of such practices.
- Market Regulation Challenges: This case reflects the growing legal gray area surrounding alternative funding programs (AFPs) in drug access, with federal authorities warning about the illegality of such imports, which could threaten patient health.
See More
Analysis of DFAC Stock's 52-Week High and Low Points
- Price Fluctuation Analysis: DFAC's 52-week low is $28.39 and high is $41.64, with the latest trade at $41.00, indicating the stock is nearing its high point, which may attract investor interest.
- Technical Analysis Tool: Comparing the latest stock price to the 200-day moving average can provide valuable insights for investors, helping to assess market trends.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting ETF liquidity.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding for ETFs helps identify those experiencing significant inflows or outflows, allowing assessment of their potential impact on underlying assets.
See More
Barron’s Top Fund Families for 2025
Opportunity for Fund Managers: Last year provided a significant opportunity for skilled fund managers to demonstrate their capabilities in navigating market challenges.
Market Conditions: The financial landscape presented unique conditions that allowed for strategic investment decisions and potential gains.
Performance Evaluation: The year served as a benchmark for assessing the effectiveness and decision-making skills of fund managers.
Investor Expectations: Investors were keenly observing how fund managers adapted to the evolving market, influencing future investment strategies.
See More
Gilead's BIC/LEN Pill Maintains Viral Suppression in HIV Trials
- Clinical Trial Results: In the ARTISTRY-1 trial, only 0.8% of patients on BIC/LEN had HIV-1 RNA ≥ 50 copies/mL, demonstrating comparable viral suppression to multi-tablet regimens, indicating the drug's effectiveness in maintaining viral control.
- Comparative Analysis: In ARTISTRY-2, 1.3% of BIC/LEN participants had HIV-1 RNA ≥ 50 copies/mL compared to 1.0% of those continuing on Biktarvy, suggesting BIC/LEN's efficacy is similar to existing treatment options, potentially influencing patient medication choices.
- Switching Advantages: BIC/LEN allows patients to switch from complex multi-drug regimens while maintaining viral suppression, simplifying treatment and potentially improving patient adherence and quality of life.
- Market Outlook: Gilead's new drug shows similar efficacy to Biktarvy, which may help it carve out a niche in the HIV treatment market, enhancing the company's competitive position in the antiviral drug sector.
See More
Gilead's New Drug Combination Shows Significant Efficacy in HIV Treatment
- Clinical Trial Results: Gilead's presentation at CROI 2026 of ARTISTRY-1 and ARTISTRY-2 trial results indicates that the BIC/LEN combination is non-inferior to complex multi-tablet regimens in maintaining HIV viral suppression, with 0.8% of participants on BIC/LEN having HIV-1 RNA ≥ 50 copies/mL at 48 weeks compared to 1.1% in the complex regimen, highlighting its therapeutic potential.
- Increased Patient Satisfaction: At 48 weeks, patient-reported treatment satisfaction in the BIC/LEN group increased by an average of 7 points, while those on complex regimens reported no significant change, indicating the new combination's advantages in patient experience and adherence.
- Good Safety Profile: The BIC/LEN combination was generally well tolerated, with drug-related adverse events reported in 14.3% of participants switching to BIC/LEN compared to 1.6% in the complex regimen, and similar rates of serious adverse events, demonstrating the safety of the new treatment option.
- Strategic Implications: These findings support Gilead's commitment to innovation in HIV treatment, as the BIC/LEN combination is poised to become a new treatment option, further expanding HIV treatment alternatives and addressing patient needs for more convenient therapies.
See More
